MINORYX THERAPEUTICS COMPLETES ENROLLMENT IN FRAMES PHASE 2 TRIAL WITH LERIGLITAZONE IN FRIEDREICH’S ATAXIA

Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019.

Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system (CNS) diseases, today announces that it has completed recruitment in the FRAMES phase 2 clinical trial of its novel PPARγ agonist, leriglitazone (MIN-102), in patients with Friedreich’s Ataxia.

FRAMES is a multicenter, randomized, double-blind, placebo-controlled trial that will assess the efficacy and safety of leriglitazone in patients with Friedreich’s Ataxia. Recruitment of 39 patients in four European countries was completed in just four and a half months, well ahead of schedule. The patients, aged 12-60 years, will receive leriglitazone, administered once a day as an oral suspension, for a total of one year. The primary objective of the trial is to monitor the effect on disease progression. This will be measured through state-of-the art imaging of the spinal cord. Secondary objectives include safety and tolerability, effect on additional clinical measures, such as patient reported outcomes, functional disability scores and exploratory biomarkers.

MINORYX THERAPEUTICS COMPLETES ENROLLMENT IN FRAMES PHASE 2 TRIAL WITH LERIGLITAZONE IN FRIEDREICH’S ATAXIA